新闻
CLLS
--
0.00%
--
威廉·布莱尔(William Blair)认为Cellectis SA的股票即将回升
SmarterAnalyst · 2天前
BRIEF-Cellectis SA Says Qtrly Loss Per Share $0.28
reuters.com · 2天前
Cellectis Q1 EPS从去年的$ 0.57下降$(0.26),从去年的$ 51.91百万下降到$ 27.97M
Cellectis (NASDAQ:CLLS) reported quarterly losses of $(0.26) per share. This is a 145.61 percent decrease over earnings of $0.57 per share from the same period last year. The company reported $27.97 million in sales
Benzinga · 2天前
BRIEF-Cellectis Posts Quarterly EPS Of $0.47
reuters.com · 2天前
Cellectis SA(CLLS)收到罗伯特·W·贝尔德(Robert W. Baird)的买入
SmarterAnalyst · 04/29 08:51
威廉·布莱尔(William Blair)维持Cellectis SA(CLLS)的买入评级
In a report released today, Raju Prasad from William Blair maintained a Buy rating on Cellectis SA (CLLS). The company's shares closed last Wednesday at
SmarterAnalyst · 04/28 16:32
DJ Cellectis从古根海姆(Guggenheim)买入降至中性
Dow Jones · 04/28 14:37
按行业份额,主要发现,公司概况,增长战略,发展中的技术,需求,投资机会和地区预测的2021年毛状细胞白血病治疗市场规模到2026年
Apr 01, 2021 (The Expresswire) -- The report provides revenue of the globalHairy Cell Leukemia Therapeutics Market for the period 2016 and 2026, considering...
The Express Wire · 04/01 06:37
每日生物技术脉搏:Wave Life Sciences锁定2项资产,Amarin的Vascepa获欧洲批准,Biocept盈利增长
Benzinga · 03/30 13:06
Baird将DJ Cellectis的股票评级从“中性”提高至优于大盘
Dow Jones · 03/16 11:37
Baird将DJ Cellectis的价格目标从23.00美元上调至39.00美元/股
Dow Jones · 03/16 11:37
Cellectis SA(CLLS)从JonesTrading获得买入评级
SmarterAnalyst · 03/05 21:15
Oppenheimer维持对Cellectis SA(CLLS)的买入
SmarterAnalyst · 03/05 19:35
Brief-Cellectis称第四季度每股亏损0.95美元
reuters.com · 03/04 23:11
Cellectis:第四季度收益洞察
Shares of Cellectis (NASDAQ:CLLS) were flatin after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 20.55% year over year to ($0.88), which missed the estimate of ($0.78). Revenue of $15,632,000 rose by 146.7...
Benzinga · 03/04 22:22
Cellectis Q4 EPS $(0.88)缺少$(0.78)估计,销售额$ 1563万,差额$ 764万,估计
Cellectis (NASDAQ:CLLS) reported quarterly losses of $(0.88) per share which missed the analyst consensus estimate of $(0.78) by 12.82 percent. This is a 20.55 percent decrease over losses of $(0.73) per share from the
Benzinga · 03/04 21:43
Cellectis,Cytovia治疗药物墨水基因编辑的治疗方法可用于肿瘤适应症
Benzinga · 02/16 13:55
Cytovia的Cellectis,以7.6亿美元合作开发天然杀伤细胞;股票上涨9%
Cytovia Therapeutics and Cellectis, a clinical stage cell therapy company announced a $760 million research and development collaboration to develop TALEN gene edited ...
TipRanks.com · 02/16 12:59
微牛提供丰富的实时CLLS股票新闻,让你可以通过多个平台了解CLLS股票行情最新动态,这些免费的Cellectis新闻可以帮助你做出明智投资。
CLLS 简况
Cellectis SA是一家活跃于基因组工程和基因组外科领域的法国公司。该公司专注于合理基因组工程技术的研究、开发和商业化。该公司开发了一种将大范围核酸酶与工程靶向脱氧核糖核酸(DNA)基质结合到大范围核酸酶重组系统(MRS)中的技术,用于基因切除、校正或替换。该公司还提供合理的反向遗传学和靶向重组工具。Cellectis SA销售的技术主要用于研究领域、药物研发项目、农业生物学、生物生产和生物治疗领域。Cellectis SA拥有多家子公司。该公司在法国和美国等地开展业务。